At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 7 enrolled
Drug / intervention
RVT-1401drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2a, Multicenter, Open-Label Study of RVT-1401 for the Treatment of Patients With Moderate to Severe Active Graves' Ophthalmopathy
In Brief
A Phase 2 clinical trial evaluating RVT-1401 for Graves' Ophthalmopathy. Completed, enrolled 7 participants across 4 sites.
Detailed Summary
The purpose of this study was to evaluate safety, tolerability, and pharmacodynamic parameters of RVT-1401 in graves' ophthalmopathy (GO) patients.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGraves' Ophthalmopathy
CountriesCanada
Collaborators--
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
First PostedApr 2019
Enrollment StartApr 2019
Primary CompletionFeb 2020
Study CompletionMay 2020
TodayJul 2026
First PostedApr 19, 2019
Enrollment StartApr 22, 2019
Primary CompletionFeb 29, 2020
Study CompletionMay 21, 2020
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 7.2 years ago
Interventions
RVT-1401drug
RVT-1401 is a fully human anti-neonatal Fc receptor (FcRn) monoclonal antibody.